|

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

RECRUITINGPhase 1Sponsored by Stemline Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorStemline Therapeutics, Inc.
Started2026-01-10
Est. completion2027-12-02
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations6 sites
View on ClinicalTrials.gov →

NCT07226427

Summary

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Key Inclusion Criteria:

* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Key Exclusion Criteria:

* Participants with primary platinum-refractory disease.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Conditions2

CancerPlatinum-resistant Ovarian Cancer

Interventions1

MEN2501

Locations6 sites

Highlands Oncology Group
Springdale, Arkansas, 72762
Yale University
New Haven, Connecticut, 06519
Florida Cancer Specialists & Research Institute
Sarasota, Florida, 34232
Karmanos Cancer Institute
Detroit, Michigan, 48201
Mayo Clinic
Rochester, Minnesota, 55905

Find trials near these locations

All trials in FloridaAll trials in MinnesotaAll trials in Virginia

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.